Molecular Partners AG American Depositary Shares (MOLN) is a publicly traded Healthcare sector company. As of May 21, 2026, MOLN trades at $3.75 with a market cap of $142.54M and a P/E ratio of 0.00. MOLN moved +6.42% today. Year to date, MOLN is -13.82%; over the trailing twelve months it is -3.86%. Its 52-week range spans $3.36 to $7.60. Analyst consensus is strong buy with an average price target of $11.00. Rallies surfaces MOLN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Molecular Partners to Present MP0712 Data at Three May Oncology Conferences: Molecular Partners will present clinical-stage Radio-DARPin candidate MP0712, targeting DLL3 in small cell lung cancer, at NIH’s SCLC Consortium on May 7, at PEGS Boston on May 13 and at Antibody & Engineering Therapeutics Basel on May 29. These oral presentations detail 212Pb-based targeted radiotherapy data across three major oncology conferences.
| Metric | Value |
|---|---|
| Price | $3.75 |
| Market Cap | $142.54M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $7.60 |
| 52-Week Low | $3.36 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
3 analysts cover MOLN: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $11.00.